Professor Rajiv Khanna obtained his doctorate degree from India and undertook his post-doctoral training at the Queensland Institute of Medical Research (QIMR), Brisbane Australia. He is the Co-Director of Queensland Immunology Research Centre and currently appointed as Distinguished Scientist at QIMR Berghofer Medical Research Institute. Prof. Khanna is also appointed as Founder and Chief Scientific Officer of Cyteph Pty Ltd, Honorary Professor at the University of Queensland and Griffith University, Brisbane, Australia. Prof. Khanna is a Fellow of Australian Academy of Health and Medical Sciences and was awarded Order of Australia in 2017. He has extensive expertise in immunotherapy clinical trials, herpesvirus immunology and vaccine development. Over the last two decades, his group has successfully translated his research towards the development of novel T cell-based immunotherapeutic strategies for the treatment of transplant recipients and autoimmune diseases. Prof. Khanna is currently appointed as a consultant to Atara Biotherapeutics, Dynavax Technologies and Cellevolve Bio for the development of novel immunotherapeutics, diagnostic technologies and vaccines. He is also appointed on Scientific Advisory Board of Atara Biotherapeutics. Prof. Khanna has been invited by various national and International organizations for expert advice on developing clinical guidelines and scientific review.